Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018-2020).
Anti-Bacterial Agents
/ pharmacology
Enterococcus faecalis
Gram-Positive Bacteria
Gram-Positive Bacterial Infections
/ drug therapy
Hospitals
Humans
Microbial Sensitivity Tests
Sepsis
/ drug therapy
Staphylococcal Infections
/ microbiology
Staphylococcus aureus
Teicoplanin
/ analogs & derivatives
United States
/ epidemiology
Bacteraemia
Dalbavancin
Lipoglycopeptide
MRSA
Staphylococcus aureus
Journal
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
17
01
2022
accepted:
22
03
2022
pubmed:
1
4
2022
medline:
27
4
2022
entrez:
31
3
2022
Statut:
ppublish
Résumé
Dalbavancin and comparators were susceptibility tested against 8643 Gram-positive bacteria from 74 hospitals located in Europe and the United States by broth microdilution method. The most common organisms were Staphylococcus aureus (45.2%), Enterococcus faecalis (12.2%), and Staphylococcus epidermidis (8.9%), but rank order varied markedly by geographic region. Dalbavancin demonstrated potent activity and broad spectrum, with MIC
Identifiants
pubmed: 35355158
doi: 10.1007/s10096-022-04437-0
pii: 10.1007/s10096-022-04437-0
pmc: PMC9033704
doi:
Substances chimiques
Anti-Bacterial Agents
0
Teicoplanin
61036-62-2
dalbavancin
808UI9MS5K
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
867-873Informations de copyright
© 2022. The Author(s).
Références
Kern WV, Rieg S (2020) Burden of bacterial bloodstream infection-a brief update on epidemiology and significance of multidrug-resistant pathogens. Clin Microbiol Infect 26(2):151–157
doi: 10.1016/j.cmi.2019.10.031
Diekema DJ, Hsueh PR, Mendes RE, Pfaller MA, Rolston KV, Sader HS, Jones RN (2019) The microbiology of bloodstream infection: 20-year trends from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 63(7):e00355
doi: 10.1128/AAC.00355-19
McNamara JF, Righi E, Wright H, Hartel GF, Harris PNA, Paterson DL (2018) Long-term morbidity and mortality following bloodstream infection: a systematic literature review. J Infect 77(1):1–8
doi: 10.1016/j.jinf.2018.03.005
Pfaller MA, Mendes RE, Duncan LR, Flamm RK, Sader HS (2018) Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015–16. J Antimicrob Chemother 73(10):2748–2756
doi: 10.1093/jac/dky235
Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW (2014) Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 370(23):2169–2179
doi: 10.1056/NEJMoa1310480
Dalvance®, (2018) Package insert. Allergan USA Inc, Madison
Smith JR, Roberts KD, Rybak MJ (2015) Dalbavancin: a novel lipoglycopeptide antibiotic with extended activity against Gram-positive infections. Infect Dis Ther 4(3):245–258
doi: 10.1007/s40121-015-0077-7
Sader HS, Mendes RE, Duncan LR, Pfaller MA, Flamm RK (2018) Antimicrobial activity of dalbavancin against Staphylococcus aureus with decreased susceptibility to glycopeptides, daptomycin, and/or linezolid from U.S. Medical Centers. Antimicrob Agents Chemother 62(3):e02397
doi: 10.1128/AAC.02397-17
Gatti M, Andreoni M, Pea F, Viale P (2021) Real-world use of dalbavancin in the era of empowerment of outpatient antimicrobial treatment: a careful appraisal beyond approved indications focusing on unmet clinical needs. Drug Des Dev Ther 15:3349–3378
doi: 10.2147/DDDT.S313756
CLSI (2018) M07ED11 Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: eleventh edition. Clinical and Laboratory Standards Institute, Wayne
CLSI (2021) M100Ed31. Performance standards for antimicrobial susceptibility testing: 31st informational supplement. Clinical and Laboratory Standards Institute, Wayne
EUCAST (2021) Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0, January 2021. European Committee on Antimicrobial Susceptibility Testing
Nunez-Nunez M, PharmD M, Casas-Hidalgo I, Garcia-Fumero R, Vallejo-Rodriguez I, Anguita-Santos F, Hernandez-Quero J, Cabeza-Barrera J, Ruiz-Sancho A (2020) Dalbavancin is a novel antimicrobial against Gram-positive pathogens: clinical experience beyond labelled indications. Eur J Hosp Pharm 27(5):310–312
doi: 10.1136/ejhpharm-2018-001711
Tobudic S, Forstner C, Burgmann H, Lagler H, Ramharter M, Steininger C, Vossen MG, Winkler S, Thalhammer F (2018) Dalbavancin as primary and sequential treatment for Gram-positive infective endocarditis: 2-year experience at the General Hospital of Vienna. Clin Infect Dis 67(5):795–798
doi: 10.1093/cid/ciy279
Gonzalez PL, Rappo U, Akinapelli K, McGregor JS, Puttagunta S, Dunne MW (2022) Outcomes in patients with Staphylococcus aureus bacteremia treated with dalbavancin in clinical trials. Infect Dis Ther 11(1):423–434
doi: 10.1007/s40121-021-00568-7
Ajaka L, Heil E, Schmalzle S (2020) Dalbavancin in the treatment of bacteremia and endocarditis in people with barriers to standard care. Antibiotics (Basel) 9(10):700
doi: 10.3390/antibiotics9100700
Cho JC, Estrada SJ, Beltran AJ, Revuelta MP (2015) Treatment of methicillin-sensitive Staphylococcus aureus bacteremia secondary to septic phlebitis using dalbavancin. J Clin Pharm Ther 40(5):604–606
doi: 10.1111/jcpt.12306
Hidalgo-Tenorio C, Vinuesa D, Plata A, Martin Davila P, Iftimie S, Sequera S, Loeches B, Lopez-Cortes LE, Farinas MC, Fernandez-Roldan C, Javier-Martinez R, Munoz P, Arenas-Miras MDM, Martinez-Marcos FJ, Miro JM, Herrero C, Bereciartua E, De Jesus SE, Pasquau J (2019) DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci. Ann Clin Microbiol Antimicrob 18(1):30
doi: 10.1186/s12941-019-0329-6
Hitzenbichler F, Mohr A, Camboni D, Simon M, Salzberger B, Hanses F (2021) Dalbavancin as long-term suppressive therapy for patients with Gram-positive bacteremia due to an intravascular source-a series of four cases. Infection 49(1):181–186
doi: 10.1007/s15010-020-01526-0
Jones BM, Keedy C, Wynn M (2018) Successful treatment of Enterococcus faecalis bacteremia with dalbavancin as an outpatient in an intravenous drug user. Int J Infect Dis 76:4–5
doi: 10.1016/j.ijid.2018.07.016
McCurdy SP, Jones RN, Mendes RE, Puttagunta S, Dunne MW (2015) In vitro activity of dalbavancin against drug resistant Staphylococcus aureus from a global surveillance program. Antimicrob Agents Chemother 59(8):5007–5009
doi: 10.1128/AAC.00274-15
Zhanel GG, Calic D, Schweizer F, Zelenitsky S, Adam H, Lagace-Wiens PR, Rubinstein E, Gin AS, Hoban DJ, Karlowsky JA (2010) New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 70(7):859–886
doi: 10.2165/11534440-000000000-00000